Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis

被引:3
|
作者
Kim, Hyejung [1 ]
Son, Ilhong [1 ,2 ]
Seol, Wongi [1 ]
机构
[1] Wonkwang Univ, InAm Neurosci Res Ctr, Sanbonro 321, Gunposi, Gyeonggido, South Korea
[2] Wonkwang Univ, Dept Neurol, Coll Med, Sanbon Med Ctr, Gunposi, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Protein synthesis; LRRK2; Parkinson's disease; G2019S; kinase; PARKINSONS-DISEASE; PHOSPHORYLATION; AUTOPHAGY; 4E-BP; P53;
D O I
10.1080/19768354.2017.1422803
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD) in an autosomal dominant manner. Pathogenic mutations of LRRK2 such as G2019S and R1441C have been observed as common genetic causes of PD. Recently, LRRK2 has been reported to increase the reporter protein synthesis in both cap-dependent and -independent manners via phosphorylation of the ribosomal protein RPS15. In this study, we tested whether LRRK2 recombinant protein would directly increase protein synthesis using a well-defined in vitro coupled transcription/translation system. Addition of commercial full-length LRRK2 or GST-fused N-terminal-deleted LRRK2 recombinant proteins to the system showed no change of protein synthesis, as measured by luciferase reporter activity. In addition, the SUnSET assay to measure newly synthesized cellular proteins showed that G2019S overexpression had a minimal effect on the total protein amount. However, we confirmed the previous result that G2019S overexpression increased the amount of protein synthesized from an exogenous gene, Flag-VAMP2, which was transfected as a reporter, whereas there was no significant change in the amount of the Flag-VAMP2 mRNA. Inhibition of protein degradation showed that protein accumulation in the vector control was higher than that of the G2019S overexpression vector. Our results suggest that LRRK2 protein influences the amount of protein by inhibiting protein degradation rather than by directly stimulating translation.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
  • [1] Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization
    Sen, Saurabh
    Webber, Philip J.
    West, Andrew B.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (52) : 36346 - 36356
  • [2] Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
    Fernandez, Belen
    Chittoor-Vinod, Vinita G.
    Kluss, Jillian H.
    Kelly, Kaela
    Bryant, Nicole
    Nguyen, An Phu Tran
    Bukhari, Syed A.
    Smith, Nathan
    Ordonez, Antonio Jesus Lara
    Fdez, Elena
    Chartier-Harlin, Marie-Christine
    Montine, Thomas J.
    Wilson, Mark A.
    Moore, Darren J.
    West, Andrew B.
    Cookson, Mark R.
    Nichols, R. Jeremy
    Hilfiker, Sabine
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (05) : 1423 - 1447
  • [3] Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors
    Greshock, Thomas J.
    Sanders, John M.
    Drolet, Robert E.
    Rajapakse, Hemaka A.
    Chang, Ronald K.
    Kim, Boyoung
    Rada, Vanessa L.
    Tiscia, Heather E.
    Su, Hua
    Lai, Ming-Tain
    Sur, Sylvie M.
    Sanchez, Rosa I.
    Bilodeau, Mark T.
    Renger, John J.
    Kern, Jonathan T.
    McCauley, John A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (11) : 2631 - 2635
  • [4] Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
    Smith, WW
    Pei, Z
    Jiang, HB
    Moore, DJ
    Liang, YD
    West, AB
    Dawson, VL
    Dawson, TM
    Ross, CA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) : 18676 - 18681
  • [5] Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date
    Morez, Margaux
    Ordonez, Antonio Jesus Lara
    Melnyk, Patricia
    Liberelle, Maxime
    Lebegue, Nicolas
    Taymans, Jean-Marc
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (09) : 773 - 788
  • [6] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [7] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Cookson, Mark R.
    NATURE REVIEWS NEUROSCIENCE, 2010, 11 (12) : 791 - 797
  • [8] Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson's Disease
    Gilligan, Paul J.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (10) : 927 - 938
  • [9] Cerebrospinal Fluid Biomarkers and Clinical Features in Leucine-Rich Repeat Kinase 2 (LRRK2) Mutation Carriers
    Vilas, Dolores
    Shaw, Leslie M.
    Taylor, Peggy
    Berg, Daniela
    Brockmann, Kathrin
    Aasly, Jan
    Marras, Connie
    Pont-Sunyer, Claustre
    Rios, Jose
    Marek, Ken
    Tolosa, Eduardo
    MOVEMENT DISORDERS, 2016, 31 (06) : 906 - 914
  • [10] Differential Effects of Divalent Manganese and Magnesium on the Kinase Activity of Leucine-Rich Repeat Kinase 2 (LRRK2)
    Lovitt, Brian
    VanderPorten, Erica C.
    Sheng, Zejuan
    Zhu, Haitao
    Drummond, Jake
    Liu, Yichin
    BIOCHEMISTRY, 2010, 49 (14) : 3092 - 3100